FDA funds research on complex generics to expand access to safe, effective generic medicines and reduce drug shortages through a more competitive, multi-sourced U.S. market.
Funder: Food and Drug Administration
Due Dates: December 14, 2026 (Application deadline, 11:59 p.m. applicant organization’s local time)
Funding Amounts: One cooperative agreement; up to $2,000,000 in year 1 and $2,500,000 annually in years 2–5
Summary: Supports collaborative complex generic drug research and workshops to improve development, regulatory assessment, patient access, and supply resilience.
Key Information: Only the University of Maryland is eligible for this single-source opportunity; only renewal applications are allowed.
The FDA’s Center for Drug Evaluation and Research (CDER) supports research addressing scientific and regulatory barriers to complex generic medicines. The program seeks to expand Americans’ access to high-quality, safe, effective, and affordable generics while reducing drug-shortage risks through a more competitive, multi-sourced U.S. market. Its goals include identifying scientific challenges, advancing collaborative research, and translating findings into scalable industry best practices aligned with modern regulatory standards.
Supported activities include scientific and educational workshops exploring emerging generic drug research trends, alongside research in analytical methods, modeling and simulation, formulation science, and clinical and preclinical development. The program emphasizes generic drug development and regulatory review, with effective engagement across scientific investigators and the generic drug industry.